Menü Kapat

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience

Original Article

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience

Receiving Date: 22 November 2021

Accept Date: 30 December 2021

Available Online: 20.03.2022

doi: 10.5455/medscience.2021.11.380

Med-Science. 2022; 11(2): 757-61

Conflict of Interests: The authors declare that they have no competing interests.
Financial Disclosure: All authors declare no financial support.
Ethical Approval: This study was approved by Fırat University Non-invasive Clinical Research Ethics Committee (date: 22.04.2021, approval number: 2021/06-09) and conducted in accordance with the Helsinki Declaration.

Table 1. Patients’ demographic and clinical features at the time of lenalidomide therapy.

 2,562 total views,  3 views today

Merter M, Uysal A.Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience. Med Science. 2022;11(2):757-61.

⇓ PlumX Meter

Corresponding Author: Mustafa Merter, Fırat University Faculty of Medicine, Department of Hematology, Elazıg, Turkey
E-mail: dr.mustafamerter@gmail.com